-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News on August 9
1.
The performance of the Chinese medicine sector is eye-catching, with 90% of companies' performance rebounding
The performance of the Chinese medicine sector is eye-catching, with 90% of companies' performance rebounding
Table 1: Top 10 listed companies with net profit growth in the first half of 2021 (according to Mi Nei.
com)
com)
At the beginning of August 2021, 126 pharmaceutical companies have shown their mid-term transcripts
.
Judging from the semi-annual reports of various Chinese medicine companies, on the one hand, in the past 2020, including Chinese medicine, the overall domestic consumption has been suppressed by the epidemic, laying the foundation for a strong rebound in 2021; on the other hand, a series of favorable policies have given the Chinese medicine sector With a cardiotonic injection, 90% of the companies achieved year-on-year growth, and their outstanding performance led the entire pharmaceutical and biological sector
.
Where PETN Church, Taiji Group, Jiaying Pharmaceutical, donkey-hide gelatin and Qizheng Tibetan medicine and other 12 companies performance have increased sharply
.
.
Judging from the semi-annual reports of various Chinese medicine companies, on the one hand, in the past 2020, including Chinese medicine, the overall domestic consumption has been suppressed by the epidemic, laying the foundation for a strong rebound in 2021; on the other hand, a series of favorable policies have given the Chinese medicine sector With a cardiotonic injection, 90% of the companies achieved year-on-year growth, and their outstanding performance led the entire pharmaceutical and biological sector
.
Where PETN Church, Taiji Group, Jiaying Pharmaceutical, donkey-hide gelatin and Qizheng Tibetan medicine and other 12 companies performance have increased sharply
.
2.
Which Chinese medicinal materials will be driven by the growth of the performance of proprietary Chinese medicines?
Which Chinese medicinal materials will be driven by the growth of the performance of proprietary Chinese medicines?
Table 2: Top 10 companies' main products and raw materials demand for net profit growth in the first half of 2021
3.
Analysis of the demand characteristics of Chinese medicinal materials for listed companies in 2021
Analysis of the demand characteristics of Chinese medicinal materials for listed companies in 2021
Through the analysis of the main products and raw materials of the top 10 companies with net profit growth in the first half of the year, our platform found the following rules:
First, the demand for raw materials related to the epidemic has increased significantly.
The most representative of this type is the Huoxiang Zhengqi series
.
Due to the good prevention and control effect of the new crown epidemic caused by cold and dampness, the sales volume of Huoxiang Zhengqi series has increased by 28.
67%, which is a significant increase, driving the demand for raw materials such as patchouli, tuckahoe, atractylodes, angelica and platycodon
.
The most representative of this type is the Huoxiang Zhengqi series
.
Due to the good prevention and control effect of the new crown epidemic caused by cold and dampness, the sales volume of Huoxiang Zhengqi series has increased by 28.
67%, which is a significant increase, driving the demand for raw materials such as patchouli, tuckahoe, atractylodes, angelica and platycodon
.
The second is the increase in demand for raw materials for immune-enhancing varieties.
Representative varieties such as Zuoli Pharmaceutical’s Wuling series, Bailing series, Lingze tablets and Linglianhua granules, etc.
, drive Wuling fungus powder, cordyceps fungus powder, zedoary turmeric, and Alisma Demand for raw materials such as growth; and Donge Ejiao series products
.
Representative varieties such as Zuoli Pharmaceutical’s Wuling series, Bailing series, Lingze tablets and Linglianhua granules, etc.
, drive Wuling fungus powder, cordyceps fungus powder, zedoary turmeric, and Alisma Demand for raw materials such as growth; and Donge Ejiao series products
.
Third, the demand for kidney-tonifying products has remained stable throughout the year.
Representative varieties such as Liuwei Dihuang series, donkey-hide gelatin series, Wuzi Yanzong series, and ancient Han health essence series have driven the growth of demand for raw materials such as rehmannia, ginseng, astragalus, and Codonopsis
.
Representative varieties such as Liuwei Dihuang series, donkey-hide gelatin series, Wuzi Yanzong series, and ancient Han health essence series have driven the growth of demand for raw materials such as rehmannia, ginseng, astragalus, and Codonopsis
.
Fourth, cardio-cerebral vascular drugs are still the main consumer.
Although the consumption growth of cardio-cerebrovascular patent medicines has slowed down compared with the past five years, it still occupies the forefront of sales of Chinese patent medicines, driving leeches, ginseng, Ophiopogon japonicus, schisandra, salvia, etc.
Demand for raw materials has grown
.
Although the consumption growth of cardio-cerebrovascular patent medicines has slowed down compared with the past five years, it still occupies the forefront of sales of Chinese patent medicines, driving leeches, ginseng, Ophiopogon japonicus, schisandra, salvia, etc.
Demand for raw materials has grown
.
In 2020, most of the growth in demand for the above categories has been feedback on the prices of raw materials.
The prices of Rehmannia, Patchouli, Poria, Leech, Alisma, etc.
have seen their price peaks in the past 20 years; while varieties such as Baizhu, Baizhi, and Codonopsis The market has also gained momentum and needs to attract the attention of demanding companies
.
The prices of Rehmannia, Patchouli, Poria, Leech, Alisma, etc.
have seen their price peaks in the past 20 years; while varieties such as Baizhu, Baizhi, and Codonopsis The market has also gained momentum and needs to attract the attention of demanding companies
.
At the same time, it should be noted that the performance growth of some companies is not entirely due to product sales profits.
For example, Qizheng Tibetan Medicine's net profit contribution point comes from external investment income, while Donge Ejiao, which is expected to turn around, is through digital transformation to enrich its product matrix.
, Achieving healthy market growth with new growth logic
.
For example, Qizheng Tibetan Medicine's net profit contribution point comes from external investment income, while Donge Ejiao, which is expected to turn around, is through digital transformation to enrich its product matrix.
, Achieving healthy market growth with new growth logic
.
Medical Network News on August 9
1.
The performance of the Chinese medicine sector is eye-catching, with 90% of companies' performance rebounding
The performance of the Chinese medicine sector is eye-catching, with 90% of companies' performance rebounding
Table 1: Top 10 listed companies with net profit growth in the first half of 2021 (according to Mi Nei.
com)
com)
At the beginning of August 2021, 126 pharmaceutical companies have shown their mid-term transcripts
.
Judging from the semi-annual reports of various Chinese medicine companies, on the one hand, in the past 2020, including Chinese medicine, the overall domestic consumption has been suppressed by the epidemic, laying the foundation for a strong rebound in 2021; on the other hand, a series of favorable policies have given the Chinese medicine sector With a cardiotonic injection, 90% of the companies achieved year-on-year growth, and their outstanding performance led the entire pharmaceutical and biological sector
.
Where PETN Church, Taiji Group, Jiaying Pharmaceutical, donkey-hide gelatin and Qizheng Tibetan medicine and other 12 companies performance have increased sharply
.
.
Judging from the semi-annual reports of various Chinese medicine companies, on the one hand, in the past 2020, including Chinese medicine, the overall domestic consumption has been suppressed by the epidemic, laying the foundation for a strong rebound in 2021; on the other hand, a series of favorable policies have given the Chinese medicine sector With a cardiotonic injection, 90% of the companies achieved year-on-year growth, and their outstanding performance led the entire pharmaceutical and biological sector
.
Where PETN Church, Taiji Group, Jiaying Pharmaceutical, donkey-hide gelatin and Qizheng Tibetan medicine and other 12 companies performance have increased sharply
.
2.
Which Chinese medicinal materials will be driven by the growth of the performance of proprietary Chinese medicines?
Which Chinese medicinal materials will be driven by the growth of the performance of proprietary Chinese medicines?
Table 2: Top 10 companies' main products and raw materials demand for net profit growth in the first half of 2021
3.
Analysis of the demand characteristics of Chinese medicinal materials for listed companies in 2021
Analysis of the demand characteristics of Chinese medicinal materials for listed companies in 2021
Through the analysis of the main products and raw materials of the top 10 companies with net profit growth in the first half of the year, our platform found the following rules:
First, the demand for raw materials related to the epidemic has increased significantly.
The most representative of this type is the Huoxiang Zhengqi series
.
Due to the good prevention and control effect of the new crown epidemic caused by cold and dampness, the sales volume of Huoxiang Zhengqi series has increased by 28.
67%, which is a significant increase, driving the demand for raw materials such as patchouli, tuckahoe, atractylodes, angelica and platycodon
.
The most representative of this type is the Huoxiang Zhengqi series
.
Due to the good prevention and control effect of the new crown epidemic caused by cold and dampness, the sales volume of Huoxiang Zhengqi series has increased by 28.
67%, which is a significant increase, driving the demand for raw materials such as patchouli, tuckahoe, atractylodes, angelica and platycodon
.
The second is the increase in demand for raw materials for immune-enhancing varieties.
Representative varieties such as Zuoli Pharmaceutical’s Wuling series, Bailing series, Lingze tablets and Linglianhua granules, etc.
, drive Wuling fungus powder, cordyceps fungus powder, zedoary turmeric, and Alisma Demand for raw materials such as growth; and Donge Ejiao series products
.
Representative varieties such as Zuoli Pharmaceutical’s Wuling series, Bailing series, Lingze tablets and Linglianhua granules, etc.
, drive Wuling fungus powder, cordyceps fungus powder, zedoary turmeric, and Alisma Demand for raw materials such as growth; and Donge Ejiao series products
.
Third, the demand for kidney-tonifying products has remained stable throughout the year.
Representative varieties such as Liuwei Dihuang series, donkey-hide gelatin series, Wuzi Yanzong series, and ancient Han health essence series have driven the growth of demand for raw materials such as rehmannia, ginseng, astragalus, and Codonopsis
.
Representative varieties such as Liuwei Dihuang series, donkey-hide gelatin series, Wuzi Yanzong series, and ancient Han health essence series have driven the growth of demand for raw materials such as rehmannia, ginseng, astragalus, and Codonopsis
.
Fourth, cardio-cerebral vascular drugs are still the main consumer.
Although the consumption growth of cardio-cerebrovascular patent medicines has slowed down compared with the past five years, it still occupies the forefront of sales of Chinese patent medicines, driving leeches, ginseng, Ophiopogon japonicus, schisandra, salvia, etc.
Demand for raw materials has grown
.
Although the consumption growth of cardio-cerebrovascular patent medicines has slowed down compared with the past five years, it still occupies the forefront of sales of Chinese patent medicines, driving leeches, ginseng, Ophiopogon japonicus, schisandra, salvia, etc.
Demand for raw materials has grown
.
In 2020, most of the growth in demand for the above categories has been feedback on the prices of raw materials.
The prices of Rehmannia, Patchouli, Poria, Leech, Alisma, etc.
have seen their price peaks in the past 20 years; while varieties such as Baizhu, Baizhi, and Codonopsis The market has also gained momentum and needs to attract the attention of demanding companies
.
The prices of Rehmannia, Patchouli, Poria, Leech, Alisma, etc.
have seen their price peaks in the past 20 years; while varieties such as Baizhu, Baizhi, and Codonopsis The market has also gained momentum and needs to attract the attention of demanding companies
.
At the same time, it should be noted that the performance growth of some companies is not entirely due to product sales profits.
For example, Qizheng Tibetan Medicine's net profit contribution point comes from external investment income, while Donge Ejiao, which is expected to turn around, is through digital transformation to enrich its product matrix.
, Achieving healthy market growth with new growth logic
.
For example, Qizheng Tibetan Medicine's net profit contribution point comes from external investment income, while Donge Ejiao, which is expected to turn around, is through digital transformation to enrich its product matrix.
, Achieving healthy market growth with new growth logic
.
Medical Network News on August 9
1.
The performance of the Chinese medicine sector is eye-catching, with 90% of companies' performance rebounding
1. The performance of the Chinese medicine sector is eye-catching, with 90% of companies' performance rebounding
The performance of the Chinese medicine sector is eye-catching, with 90% of companies' performance rebounding
Table 1: Top 10 listed companies with net profit growth in the first half of 2021 (according to Mi Nei.
com)
com)
At the beginning of August 2021, 126 pharmaceutical companies have shown their mid-term transcripts
.
Judging from the semi-annual reports of various Chinese medicine companies, on the one hand, in the past 2020, including Chinese medicine, the overall domestic consumption has been suppressed by the epidemic, laying the foundation for a strong rebound in 2021; on the other hand, a series of favorable policies have given the Chinese medicine sector With a cardiotonic injection, 90% of the companies achieved year-on-year growth, and their outstanding performance led the entire pharmaceutical and biological sector
.
Where PETN Church, Taiji Group, Jiaying Pharmaceutical, donkey-hide gelatin and Qizheng Tibetan medicine and other 12 companies performance have increased sharply
.
Pharmaceutical Pharmaceutical Pharmaceutical Enterprise Enterprise Enterprise.
Judging from the semi-annual reports of various Chinese medicine companies, on the one hand, in the past 2020, including Chinese medicine, the overall domestic consumption has been suppressed by the epidemic, laying the foundation for a strong rebound in 2021; on the other hand, a series of favorable policies have given the Chinese medicine sector With a cardiotonic injection, 90% of the companies achieved year-on-year growth, and their outstanding performance led the entire pharmaceutical and biological sector
.
Where PETN Church, Taiji Group, Jiaying Pharmaceutical, donkey-hide gelatin and Qizheng Tibetan medicine and other 12 companies performance have increased sharply
.
2.
Which Chinese medicinal materials will be driven by the growth of the performance of proprietary Chinese medicines?
2. Which Chinese medicinal materials will be driven by the growth of the performance of proprietary Chinese medicines?
Which Chinese medicinal materials will be driven by the growth of the performance of proprietary Chinese medicines?
Table 2: Top 10 companies' main products and raw materials demand for net profit growth in the first half of 2021
3.
Analysis of the demand characteristics of Chinese medicinal materials for listed companies in 2021
3. Analysis of the demand characteristics of Chinese medicinal materials for listed companies in 2021
Analysis of the demand characteristics of Chinese medicinal materials for listed companies in 2021
Through the analysis of the main products and raw materials of the top 10 companies with net profit growth in the first half of the year, our platform found the following rules:
First, the demand for raw materials related to the epidemic has increased significantly.
The most representative of this type is the Huoxiang Zhengqi series
.
Due to the good prevention and control effect of the new crown epidemic caused by cold and dampness, the sales volume of Huoxiang Zhengqi series has increased by 28.
67%, which is a significant increase, driving the demand for raw materials such as patchouli, tuckahoe, atractylodes, angelica and platycodon
.
The most representative of this type is the Huoxiang Zhengqi series
.
Due to the good prevention and control effect of the new crown epidemic caused by cold and dampness, the sales volume of Huoxiang Zhengqi series has increased by 28.
67%, which is a significant increase, driving the demand for raw materials such as patchouli, tuckahoe, atractylodes, angelica and platycodon
.
The second is the increase in demand for raw materials for immune-enhancing varieties.
Representative varieties such as Zuoli Pharmaceutical’s Wuling series, Bailing series, Lingze tablets and Linglianhua granules, etc.
, drive Wuling fungus powder, cordyceps fungus powder, zedoary turmeric, and Alisma Demand for raw materials such as growth; and Donge Ejiao series products
.
Representative varieties such as Zuoli Pharmaceutical’s Wuling series, Bailing series, Lingze tablets and Linglianhua granules, etc.
, drive Wuling fungus powder, cordyceps fungus powder, zedoary turmeric, and Alisma Demand for raw materials such as growth; and Donge Ejiao series products
.
Third, the demand for kidney-tonifying products has remained stable throughout the year.
Representative varieties such as Liuwei Dihuang series, donkey-hide gelatin series, Wuzi Yanzong series, and ancient Han health essence series have driven the growth of demand for raw materials such as rehmannia, ginseng, astragalus, and Codonopsis
.
Health health healthRepresentative varieties such as Liuwei Dihuang series, donkey-hide gelatin series, Wuzi Yanzong series, and ancient Han health essence series have driven the growth of demand for raw materials such as rehmannia, ginseng, astragalus, and Codonopsis
.
Fourth, cardio-cerebral vascular drugs are still the main consumer.
Although the consumption growth of cardio-cerebrovascular patent medicines has slowed down compared with the past five years, it still occupies the forefront of sales of Chinese patent medicines, driving leeches, ginseng, Ophiopogon japonicus, schisandra, salvia, etc.
Demand for raw materials has grown
.
Although the consumption growth of cardio-cerebrovascular patent medicines has slowed down compared with the past five years, it still occupies the forefront of sales of Chinese patent medicines, driving leeches, ginseng, Ophiopogon japonicus, schisandra, salvia, etc.
Demand for raw materials has grown
.
In 2020, most of the growth in demand for the above categories has been feedback on the prices of raw materials.
The prices of Rehmannia, Patchouli, Poria, Leech, Alisma, etc.
have seen their price peaks in the past 20 years; while varieties such as Baizhu, Baizhi, and Codonopsis The market has also gained momentum and needs to attract the attention of demanding companies
.
The prices of Rehmannia, Patchouli, Poria, Leech, Alisma, etc.
have seen their price peaks in the past 20 years; while varieties such as Baizhu, Baizhi, and Codonopsis The market has also gained momentum and needs to attract the attention of demanding companies
.
At the same time, it should be noted that the performance growth of some companies is not entirely due to product sales profits.
For example, Qizheng Tibetan Medicine's net profit contribution point comes from external investment income, while Donge Ejiao, which is expected to turn around, is through digital transformation to enrich its product matrix.
, Achieving healthy market growth with new growth logic
.
For example, Qizheng Tibetan Medicine's net profit contribution point comes from external investment income, while Donge Ejiao, which is expected to turn around, is through digital transformation to enrich its product matrix.
, Achieving healthy market growth with new growth logic
.
